ArticleFuture oncology (London, England)2024
IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma.
Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- CD112 Lactylation Drives Dual Immune Evasion From CD8+ T Cells and NK Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Right Key, the Wrong Lock: TIGIT Checkpoint Blockade and the Road to Precision Immunotherapy.Pharmaceutics · 2026Review
- First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.Journal of clinical medicine · 2026Article
- Review
- Vorinostat unmasks MAEL to enhance DC vaccine-induced CTL killing in hepatocellular carcinoma, potentiated by TIGIT checkpoint inhibition.Cancer immunology, immunotherapy : CII · 2026Article
- Article
- Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.Journal of gastrointestinal oncology · 2026Article
- Review
- Clinical efficacy and safety of drug-eluting bead transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors in the treatment of intermediate-to-advanced hepatocellular carcinoma.Pakistan journal of medical sciences · 2026Article
- Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies.Frontiers in medicine · 2026Review
- Combined Immunotherapy in Treating Patients with Advanced Hepatocellular Carcinoma.Biomedicines · 2025Review
- Integrated bulk and single-cell transcriptomic profiling reveals NECTIN-TIGIT interaction underlies T cell exhaustion in papillary thyroid carcinoma.Clinical and experimental medicine · 2025Article
- Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.Cancer immunology, immunotherapy : CII · 2025Article
- Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide.JCO oncology practice · 2025Review
- Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects.Current oncology (Toronto, Ont.) · 2025Review
- Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2025Review
- Immunometabolic Targets in CD8Liver cancer · 2025Review
- A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma.Journal of experimental & clinical cancer research : CR · 2025Article
- Next-Generation Immunotherapy for Hepatocellular Carcinoma: Mechanisms of Resistance and Novel Treatment Approaches.Cancers · 2025Review
- Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Atezolizumab plus bevacizumab is a standard of care, first-line therapy for advanced hepatocellular carcinoma (HCC). Myeloid and T regulatory cells are key immunosuppressive cell types within the hepatic tumor microenvironment associated with clinical resistance to atezolizumab and bevacizumab therapy for HCC and overall poor prognosis. Therapeutic targeting of TIGIT, which is highly expressed in these cells, with tiragolumab may overcome the immunosuppressive environment and improve clinical benefit, a hypothesis supported by positive efficacy signals in the Phase Ib/II MORPHEUS-Liver study. This paper describes the rationale and design of IMbrave152/SKYSCRAPER-14, a randomized, double-blind, placebo-controlled Phase III study comparing atezolizumab and bevacizumab with tiragolumab or placebo in patients with HCC and no prior systemic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.